Enveric Biosciences Inc (ENVB) - Net Assets
Based on the latest financial reports, Enveric Biosciences Inc (ENVB) has net assets worth $3.46 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.36 Million) and total liabilities ($905.88K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ENVB asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.46 Million |
| % of Total Assets | 79.23% |
| Annual Growth Rate | 0.43% |
| 5-Year Change | -53.37% |
| 10-Year Change | 516.09% |
| Growth Volatility | 902.41 |
Enveric Biosciences Inc - Net Assets Trend (1994–2024)
This chart illustrates how Enveric Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Also explore ENVB total assets for the complete picture of this company's asset base.
Annual Net Assets for Enveric Biosciences Inc (1994–2024)
The table below shows the annual net assets of Enveric Biosciences Inc from 1994 to 2024. For live valuation and market cap data, see Enveric Biosciences Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.59 Million | -18.58% |
| 2023-12-31 | $1.96 Million | -87.42% |
| 2022-12-31 | $15.56 Million | -30.26% |
| 2021-12-31 | $22.31 Million | +553.05% |
| 2020-12-31 | $3.42 Million | -67.84% |
| 2019-12-31 | $10.62 Million | -1.28% |
| 2018-12-31 | $10.76 Million | -44.68% |
| 2017-12-31 | $19.45 Million | +66.74% |
| 2016-12-31 | $11.66 Million | +4411.49% |
| 2015-12-31 | $258.53K | +6778.71% |
| 2014-12-31 | $-3.87K | +80.86% |
| 2013-12-31 | $-20.23K | -0.80% |
| 2012-12-31 | $-20.07K | -540.53% |
| 2011-12-31 | $4.55K | +109.20% |
| 2010-12-31 | $-49.52K | -391.47% |
| 2009-12-31 | $-10.07K | -120.79% |
| 2008-12-31 | $48.47K | -96.89% |
| 2007-12-31 | $1.56 Million | +313.57% |
| 2006-12-31 | $376.50K | -47.52% |
| 2005-12-31 | $717.40K | -10.07% |
| 2004-12-31 | $797.74K | -16.50% |
| 2003-12-31 | $955.38K | -33.14% |
| 2002-12-31 | $1.43 Million | +1.22% |
| 2001-12-31 | $1.41 Million | -14.49% |
| 2000-12-31 | $1.65 Million | +114.89% |
| 1999-12-31 | $768.14K | +149.45% |
| 1998-12-31 | $-1.55 Million | -201.86% |
| 1997-12-31 | $1.53 Million | -53.33% |
| 1996-12-31 | $3.27 Million | -11.68% |
| 1995-12-31 | $3.70 Million | +164.29% |
| 1994-12-31 | $1.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Enveric Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9927450500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.78K | 0.43% |
| Other Comprehensive Income | $-594.52K | -37.33% |
| Other Components | $108.26 Million | 6796.50% |
| Total Equity | $1.59 Million | 100.00% |
Enveric Biosciences Inc Competitors by Market Cap
The table below lists competitors of Enveric Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BioRestorative Therapies Inc
NASDAQ:BRTX
|
$2.07 Million |
|
Baillie Gifford China Growth Trust PLC
LSE:BGCG
|
$2.07 Million |
|
Qiiwi Games AB (publ)
ST:QIIWI
|
$2.07 Million |
|
Greenwave Technology Solutions Inc. Common Stock
NASDAQ:GWAV
|
$2.07 Million |
|
Fonix Mobile plc
LSE:FNX
|
$2.06 Million |
|
Careteq Ltd
AU:CTQ
|
$2.06 Million |
|
Fastator AB
ST:FASTAT
|
$2.06 Million |
|
Aker Carbon Capture ASA
OL:ACC
|
$2.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Enveric Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,956,336 to 1,592,807, a change of -363,529 (-18.6%).
- Net loss of 9,574,987 reduced equity.
- Share repurchases of 1,083,706 reduced equity.
- New share issuances of 3,373,892 increased equity.
- Other comprehensive income decreased equity by 24,768.
- Other factors increased equity by 6,946,040.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.57 Million | -601.14% |
| Share Repurchases | $1.08 Million | -68.04% |
| Share Issuances | $3.37 Million | +211.82% |
| Other Comprehensive Income | $-24.77K | -1.55% |
| Other Changes | $6.95 Million | +436.09% |
| Total Change | $- | -18.58% |
Book Value vs Market Value Analysis
This analysis compares Enveric Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.10x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.10x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1994-12-31 | $12727.27 | $3.99 | x |
| 1995-12-31 | $33636.36 | $3.99 | x |
| 1996-12-31 | $29707.94 | $3.99 | x |
| 1997-12-31 | $13864.66 | $3.99 | x |
| 1998-12-31 | $-14122.64 | $3.99 | x |
| 1999-12-31 | $6983.06 | $3.99 | x |
| 2000-12-31 | $15006.14 | $3.99 | x |
| 2001-12-31 | $12832.44 | $3.99 | x |
| 2002-12-31 | $12989.38 | $3.99 | x |
| 2003-12-31 | $8685.26 | $3.99 | x |
| 2004-12-31 | $7252.14 | $3.99 | x |
| 2005-12-31 | $6521.84 | $3.99 | x |
| 2006-12-31 | $3422.74 | $3.99 | x |
| 2007-12-31 | $14155.50 | $3.99 | x |
| 2008-12-31 | $440.63 | $3.99 | x |
| 2009-12-31 | $-91.59 | $3.99 | x |
| 2010-12-31 | $-450.15 | $3.99 | x |
| 2011-12-31 | $41.41 | $3.99 | x |
| 2012-12-31 | $-182.42 | $3.99 | x |
| 2013-12-31 | $-183.88 | $3.99 | x |
| 2014-12-31 | $-35.19 | $3.99 | x |
| 2015-12-31 | $1397.48 | $3.99 | x |
| 2016-12-31 | $53487.71 | $3.99 | x |
| 2017-12-31 | $77779.20 | $3.99 | x |
| 2018-12-31 | $27169.44 | $3.99 | x |
| 2019-12-31 | $18094.63 | $3.99 | x |
| 2020-12-31 | $5345.29 | $3.99 | x |
| 2021-12-31 | $8500.73 | $3.99 | x |
| 2022-12-31 | $1826.46 | $3.99 | x |
| 2023-12-31 | $163.10 | $3.99 | x |
| 2024-12-31 | $38.01 | $3.99 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Enveric Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -601.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.94x
- Recent ROE (-601.14%) is below the historical average (-145.79%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1994 | -85.71% | -600.00% | 0.09x | 1.64x | $-1.34 Million |
| 1995 | -86.49% | -266.67% | 0.27x | 1.19x | $-3.57 Million |
| 1996 | -777.12% | -1254.59% | 0.49x | 1.27x | $-25.72 Million |
| 1997 | -309.47% | -169.70% | 0.88x | 2.08x | $-4.87 Million |
| 1998 | 0.00% | -344.82% | 1.88x | 0.00x | $-5.64 Million |
| 1999 | 46.19% | 21.37% | 0.78x | 2.76x | $277.98K |
| 2000 | 23.14% | 17.35% | 0.90x | 1.49x | $216.95K |
| 2001 | -17.01% | -14.97% | 0.91x | 1.24x | $-381.26K |
| 2002 | 1.28% | 0.99% | 1.06x | 1.22x | $-124.59K |
| 2003 | -51.86% | -39.03% | 1.05x | 1.26x | $-590.99K |
| 2004 | -19.74% | -14.24% | 0.76x | 1.84x | $-237.26K |
| 2005 | -11.36% | -6.84% | 1.33x | 1.25x | $-153.26K |
| 2006 | -93.66% | -105.83% | 0.72x | 1.23x | $-390.28K |
| 2007 | 51.84% | 107.54% | 0.47x | 1.03x | $651.57K |
| 2008 | -296.35% | 0.00% | 0.00x | 1.44x | $-148.48K |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-57.54K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-34.49K |
| 2011 | -732.82% | 0.00% | 0.00x | 4.93x | $-33.84K |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-22.61K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $1.86K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-33.26K |
| 2015 | -731.34% | -11.83% | 1.15x | 53.51x | $-1.92 Million |
| 2016 | -23.85% | -7.69% | 0.91x | 3.39x | $-3.95 Million |
| 2017 | -46.67% | -18.67% | 0.93x | 2.68x | $-11.02 Million |
| 2018 | -157.05% | -39.30% | 1.45x | 2.75x | $-17.97 Million |
| 2019 | -52.76% | -14.04% | 1.60x | 2.35x | $-6.67 Million |
| 2020 | -200.98% | -17.20% | 9.74x | 1.20x | $-7.21 Million |
| 2021 | -219.57% | 0.00% | 0.00x | 1.20x | $-51.21 Million |
| 2022 | -126.12% | 0.00% | 0.00x | 1.33x | $-19.97 Million |
| 2023 | -0.88% | 0.00% | 0.00x | 2.20x | $-212.93K |
| 2024 | -601.14% | 0.00% | 0.00x | 1.94x | $-9.73 Million |
Industry Comparison
This section compares Enveric Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Enveric Biosciences Inc (ENVB) | $3.46 Million | -85.71% | 0.26x | $2.07 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Enveric Biosciences Inc
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage fo… Read more